This may be explained by advances in supportive care, including routine use of mould‐active prophylaxis6 as well as routine use of early G‐CSF; the latter resulting in an apparent shorter duration of neutropenia in our cohort relative to other series, such as the RADIUS‐X expanded access midostaurin program (median 22 vs 26 days).26 The gene discussed is CSF3; the disease is Decreased total neutrophil count.